Barbeau A.Parkinson's disease: clinical features and etiopathology. In: Vinken PJ, Bruyn GW, Klawans H, eds. Extrapyramidal disorders. Amsterdam: Elsevier Science Publishers, 1986:87-152. (Handbook of clinical neurology; vol 5.)
2.
Forno LSPathology of Parkinson's disease. In: Mars-den SC, Fahn S, eds. Movement disorders. London: Butterworths & Co., 1981.
3.
Rinne UK, Sonninen V., Shrtola T.L-Dopa treatment in Parkinson's disease. Eur Neurol1970;4:348-69.
4.
Hyppa M., Rinne UK, Sonninen V.The activating effect of L-Dopa treatment of sexual functions and its experimental background. Acta Neurol Scand1970;46 (suppl 43):223-4.
5.
Harvey NSPsychiatric disorders in parkinsonism: 2. Organic cerebral states and drug reactions. Psychosomatics1986;27:175-7.
6.
Shapiro SKHypersexual behavior complicating levodopa (L-Dopa) therapy. Minn Med1973;56:58-9.
7.
Vogel HP, Schiffter R.Hypersexuality—acomplication of dopaminergic therapy in Parkinson's disease. Pharmacopsychiatry1983;16:107-10.
8.
Sacks O., Kohl M.Incontinent nostalgia induced by L-Dopa. Lancet1970;1:1394.
9.
O'Brien CP, DiGiacomo JN, Fahn S., Schwartz GAMental effects of high dose levodopa. Arch Gen Psychiatry1971;24:61-4.
10.
Brown E., Brown G., Kofman O., Quarrington B.Sexual function and affect in parkinsonian men treated with L-Dopa . Am J Psychiatry1978;135:1552-5.
11.
Pekkarinen A., Rinne UK, Solokangas T., Siirtola T., Sonninen V.Plasma testosterone content of male patients with Parkinson's disease during L-Dopa treatment with or without dopadecarboxylase inhibitor. Acta Neurol Scand1972;51 (suppl):129-30.
12.
Rinne UK, Sonninen V., Siirtola T.Acid monoamine metabolites in the cerebrospinal fluid of parkinsonian patients treated with levodopa alone or combined with a dopadecarboxylase inhibitor . Eur Neurol1973;9: 349-62.